AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00661089
Drug: Placebo (Saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
Trial: NCT04322032
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.
Trial: NCT04322032
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.
Trial: NCT05186129
Drug: Clopid® 75 mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Clopid® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
Trial: NCT05186129
Drug: Plavix® 75mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Plavix® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
Trial: NCT02038179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.
Trial: NCT02056418
Drug: corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
Trial: NCT04361422
Drug: Isotretinoin Only Product in Oral Dose Form
RxNorm normalized name: Isotretinoin only product in oral dose form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
Trial: NCT01209403
Drug: Glucose-infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous iv infusion of glucose
Trial: NCT01209403
Drug: Glucose-insulin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous iv infusion of glucose and shortlasting
Trial: NCT00687908
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel to the face, once daily in the evening for 24 weeks.
Trial: NCT03003247
Drug: IDP-120 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-120 Gel is a combination product
Trial: NCT03003247
Drug: IDP 120 Vehicle Gel
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT03576638
Drug: Accordion Pill Carbidopa/Levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP 50/500 TID days 2-7
Trial: NCT03576638
Drug: Sinemet CR 25Mg-100Mg Extended-Release Tablet
RxNorm normalized name: Sinemet CR 25mg-100mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25/100 1.5 pills five times/day
Trial: NCT00300222
Drug: NGX-4010
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04202497
Drug: [18F]MNI-1054 (radiotracer)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]MNI-1054 injection.
Trial: NCT03627013
Drug: Custodiol-N Solution
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion
Trial: NCT03627013
Drug: Custodiol HTK Solution
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion
Trial: NCT02097173
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04351724
Drug: Thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as local standard, most likely to be low molecular weight heparin
Trial: NCT00030654
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00802646
Drug: fentanyl/bupivacaine/epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
Trial: NCT01655225
Drug: LY3023414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.
Trial: NCT01145664
Drug: Herbal concentrate-granules plus western therapy
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention time: 7-10 days; Follow-up time: 5 days.
Trial: NCT01145664
Drug: Western therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention time: 7-10 days; Follow-up time: 5 days.
Trial: NCT00955799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind treatment period of 29 weeks placebo
Trial: NCT01483638
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will be administered orally with the same schedule of axitinib
Trial: NCT01348724
Drug: [14C] NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 25 mg oral dose administered on Day 1
Trial: NCT06312800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
Trial: NCT03812900
Drug: Echinacea purpurea alcoholic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
Trial: NCT00254865
Drug: EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02134093
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous pump infusion normal saline with identical volume of dexmedetomidine.
Trial: NCT00293059
Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
Trial: NCT00293059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to be taken orally daily.
Trial: NCT02134093
Drug: Maintenance of anesthesia , propofol, remifentanil,vecuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.
Trial: NCT02627196
Drug: Medical Management
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01660867
Drug: 3% saline + oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebulized epinephrine + 3% saline + placebo =\> nebulized epinephrine + 3% saline
Trial: NCT02949349
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
Trial: NCT01791595
Drug: AZD3965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -7: single dose of 5 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 5 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Trial: NCT01791595
Drug: AZD3965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -7: single dose of 10 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Trial: NCT01791595
Drug: AZD3965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 20 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Trial: NCT01791595
Drug: AZD3965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 30 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Trial: NCT01791595
Drug: AZD3965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 15 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Trial: NCT01791595
Drug: AZD3965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Trial: NCT01791595
Drug: AZD3965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment (first 3 trial participants in the Expansion Cohort only; subsequent patients started treatment at Cycle 1, Day 1).~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Trial: NCT02949349
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily dose not more than 10mg, orally, for 24 weeks.
Trial: NCT03294694
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.
Trial: NCT04602494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
Trial: NCT03844776
Drug: Co-Amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin + clavulanic acid orally
Trial: NCT00338767
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication treatment includes flouxetine for treatment of depression.
Trial: NCT03428568
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT03289390
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
Trial: NCT00029393
Drug: Immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03844776
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline irrigation
Trial: NCT01623921
Drug: standard care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Trial: NCT01623921
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Trial: NCT01623921
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Trial: NCT01699724
Drug: JZoloft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tablet on Day 1 of each period
Trial: NCT01919164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Placebo matched to sprifermin as intra-articular injection.
Trial: NCT03338881
Drug: [14C]-TAK-659
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-TAK-659 solution.
Trial: NCT00062595
Drug: phylloquinone (K1)
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02100839
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline for injection
Trial: NCT00018824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02079480
Drug: Placebo matching with BMS-986090
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04094168
Drug: DEL NIDO CARDIOPLEGIA
RxNorm normalized name: Del Nido Cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).~Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq.
Trial: NCT04094168
Drug: COLD BLOOD BASED CARDIOPLEGIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
Trial: NCT00104182
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04787887
Drug: EU-sourced Cerezyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60IU/kg Single Intravenous Administration
Trial: NCT00649636
Drug: Fluoxetine Capsules 40 mg
RxNorm normalized name: fluoxetine Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg, single dose fasting
Trial: NCT01463917
Drug: Hypertonic solution
RxNorm normalized name: Hypertonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
Trial: NCT01463917
Drug: Isotonic
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
Trial: NCT00664352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site.
Trial: NCT01557478
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
Trial: NCT01557478
Drug: match placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
Trial: NCT03569098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators will inject the reconstituted solution into foot muscles.
Trial: NCT02007317
Drug: Oshadi D & Oshadi R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti tumor agents
Trial: NCT00478270
Drug: ibandronate [Bondronat]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg iv on days 1-3
Trial: NCT03337815
Drug: Treatment of MTX and TwHF placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg,3 times a day, oral, for 24 weeks.
Trial: NCT03337815
Drug: Treatment of TwHF and MTX placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium wilfordii Hook F（TwHF)：20mg,3 times a day, oral, for 24 weeks.Methotrexate (MTX)placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
Trial: NCT00001322
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal Estradiol, 100mcg/day by skin patch
Trial: NCT00001322
Drug: Placebo suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppository twice daily
Trial: NCT00001322
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by skin patch
Trial: NCT00129441
Drug: Merck L-830982
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
Trial: NCT00129441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
Trial: NCT01897337
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
Trial: NCT00667329
Drug: 2CdA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/m\^2 subcutaneous injection three times daily x 7 days.
Trial: NCT00667329
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/m\^2 PO twice daily x 7 days.
Trial: NCT04622917
Drug: MethylPREDNISolone 40 Mg/mL Injectable Suspension
RxNorm normalized name: methylPREDNISolone 40 mg/mL injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular injection
Trial: NCT00047710
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 650mg/m\^2 taken by mouth twice a day 15-52 during the radiotherapy.
Trial: NCT04622917
Drug: NaCl 9 MG/ML Injectable Solution
RxNorm normalized name: NaCl 9 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT01053156
Drug: minocycline hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline hydrochloride dosed orally once a day for 3 months.
Trial: NCT01053156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given daily for 3 months.
Trial: NCT02121795
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/300 mg FDC tablets administered orally once daily
Trial: NCT02121795
Drug: Allowed third antiretroviral agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
Trial: NCT02121795
Drug: FTC/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT02121795
Drug: F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT02752815
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03076359
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
Trial: NCT01179607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03645642
Drug: Diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
Trial: NCT00395850
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks